<DOC>
	<DOCNO>NCT03051581</DOCNO>
	<brief_summary>The purpose study evaluate whether 18F-FDG PET/CT-based prognostic model PTCL predict disease progression</brief_summary>
	<brief_title>18F-FDG PET/CT-based Prognostic Model Predicting Outcome Patients With Peripheral T-cell Lymphoma</brief_title>
	<detailed_description>In study investigator develop prognostic model base 18F-FDG PET/CT test ability prognostic value patient DLBCL . PET/CT scan evaluation use liver SUVmax reference . Positive lesion PET indicate SUVmax residue higher threshold new 18F-FDG avid lesion . 18F-FDG PET/CT-based prognostic model include PET/CT image , dominant clinical pathological prognostic factor predict disease progression chemotherapy survival PTCL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>newly diagnose PTCL treat use anthracyclinecontaining regimen minimal followup 6 month completion firstline treatment complete medical history clinicopathological data secondary malignant disease serious infection inflammation ( e.g. , HIV ) primary central nervous system lymphoma hepatic renal dysfunction .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lymphoma , T-Cell , Peripheral</keyword>
	<keyword>Positron-Emission Tomography</keyword>
	<keyword>Prognosis</keyword>
</DOC>